Based on clinical observations and indirect comparisons from studies like SURPASS-2 and SUSTAIN FORTE, which examined the efficacy of different doses against common comparators (such as semaglutide 1 mg): Lower Doses: Semaglutide 0.5 mg weekly has been roughly correlated with tirzepatide 2.5 mg to 5 mg weekly in terms of initial therapeutic effect, particularly concerning glycemic control and early weight loss
Archives of toxicology, 86, 521-534
Semaglutide (STEP 1 trial): Participants lost an average of 14.9% of body weight over 68 weeks at the 2.4 mg dose, compared to 2.4% with placebo
Defects in complexes I, III, IV, and V were also reported in a few other studies on the mitochondria isolated from autistic children [75,76,77]
This is very important in order to prevent hypoglycaemia, sugar cravings, foggy head and fatigue
some consider ethnicity and broader risk factors